Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €7.72 EUR
Change Today -0.18 / -2.28%
Volume 18.9K
ALMED On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
As of 11:22 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

medicrea international (ALMED) Snapshot

Open
€7.90
Previous Close
€7.90
Day High
€7.90
Day Low
€7.67
52 Week High
08/1/14 - €10.27
52 Week Low
06/29/15 - €7.10
Market Cap
69.5M
Average Volume 10 Days
5.7K
EPS TTM
€-0.12
Shares Outstanding
9.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICREA INTERNATIONAL (ALMED)

Related News

No related news articles were found.

medicrea international (ALMED) Related Businessweek News

No Related Businessweek News Found

medicrea international (ALMED) Details

Medicrea designs, develops, manufactures, and distributes orthopedic implants in France. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracic fixation; and PASS ANT, a polyaxial low profile thoraco-lumbar system for anterior approach. The company also provides a range of implants for the cervical spine, including C-JAWS, an anterior cervical spinal fixation system; IMPIX C, a sterile PEEK Optima cervical inter body device; Impix C+, a sterile PEEK Optima cervical inter body device that is prefilled with bone substitutes; and MANTA, a sterile PEEK Optima cervical inter body device, which is preassembled on holder and delivers with disposable instrumentation kit. Its implants for cervical spine also include MANTA +, a sterile PEEK Optima cervical inter body device, which is prefilled with bone substitutes, as well as preassembled on disposable holder and delivered with disposable instrumentation kit; and GRANVIA C, a MRI compatible ceramic cervical disc. In addition, the company offers implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar inter body device for posterior approach; IMPIX-TLIF, a sterile peek optima lumbar inter body device for transformational approach; IMPIX ALIF, a sterile PEEK Optima lumbar inter body device for anterior approach; STABOLT, a lumbosacral anterior plating system; and OSMOSYS, a macro porous bone substitute. Its implants are designed to treat scoliosis, degenerative deformation, trauma, and tumors; and are used in various traditional and advanced surgical techniques, such as minimally-invasive surgery. The company was founded in 1990 and is headquartered in Lyon, France.

119 Employees
Last Reported Date: 04/29/15
Founded in 1990

medicrea international (ALMED) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medicrea international (ALMED) Key Developments

Medicrea Reports Financial Results for the Second Quarter and First Half of 2015

Medicrea reported financial results for the second quarter and first half of 2015. For the first half, total revenue was €13.8 million ($17.4 million), increasing 16% from €11.9 million ($16.3 million) a year ago. For the quarter, revenue was €8.0 million ($8.9 million), increasing 23% from €6.5 million ($8.9 million) a year ago period, due to the expansion of its distribution network in Eastern Europe, Gulf States, and Southeast Asia and deployment of a new export sales team.

Medicrea Reports Sales Results for the Second Quarter and First Half of 2015

Medicrea reported sales results for the second quarter and first half of 2015. For the second quarter of 2015, the company reported sales results of EUR 6.50 million against EUR 8.00 million a year ago. For the first half of 2015, the company reported sales results of EUR 11.90 million against EUR 13.80 million a year ago. The increase in sales was driven in part by a particularly dynamic second quarter reflecting the first positive effects of the aggressive international strategy instigated in 2014 with the deployment of a new export sales team.

Medicrea Presents at French Life Science Days conference, Jun-17-2015

Medicrea Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALMED:FP €7.72 EUR -0.18

ALMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALMED.
View Industry Companies
 

Industry Analysis

ALMED

Industry Average

Valuation ALMED Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICREA INTERNATIONAL, please visit www.medicrea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.